Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries

Last updated: August 21, 2025
Sponsor: University of Las Palmas de Gran Canaria
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Non-invasive Neuromodulation

Placebo Non-invasive Neuromodulation

Clinical Study ID

NCT05207943
NESALCA
  • Ages > 16
  • All Genders

Study Summary

Injury to the anterior cruciate ligament (ACL) is very common among sports professionals and the general population [. Unlike other joint injuries, it is reversible, but it can damage adjacent tissues, particularly the meniscus, and catalyze knee osteoarthritis.

ACL injury produces instability, joint mechanical alteration, which can lead to degenerative joint diseases. The goal of treating the injury will be to prevent symptomatic instability, restore normal knee kinematics, and prevent degenerative joint disease .

Its usual treatment is surgical and therefore contributes to a significant cost for the health system, both for the surgeries themselves, and for the rehabilitation and subsequent recovery processes.

Within recovery therapies, in some cases, and given their popularity within the world of physiotherapy, electrotherapy techniques are proposed, primarily transcutaneous electrical nerve stimulation-type techniques with action on the muscular system and analgesia.

An early intervention with neuromuscular electrostimulation electrotherapy (NMES) combined with repeated exercises is effective for the recovery of strength and restoration of the biomechanical symmetry of the limb.

There is a diversity of opinions and disparate results regarding the use of this type of technique , in any case, it has been shown that electrical stimulation favors cell migration and joint tissue regeneration.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Over 16 years old

  • In normal conditions and mentally competent to participate in the study.

  • Not having previous knee surgeries.

  • In condition to complete the study questionnaires.

Exclusion

Exclusion Criteria:

  • Present some of the contraindications for a treatment with NESA XSIGNAL®:pacemakers, internal bleeding, do not apply electrodes on skin in poor condition,with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and / orelectricity phobia.

  • Not having signed the informed consent.

  • Urgent surgical interventions.

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Non-invasive Neuromodulation
Phase:
Study Start date:
May 25, 2021
Estimated Completion Date:
December 25, 2025

Study Description

The design of this study is a randomised, triple blind clinical trial with placebo control.

The general configuration of the study consists of capturing a group of patients treated with the same ACL surgical technique, operated on by the same surgeon, and including an additional treatment with the NESA XSIGNAL® device in a group of them.

For this, a double-blind capture system will be available (neither users nor specialists responsible for recovery will know which patients enter the complementary treatment) and two NESA XSIGNAL® devices operating double-blind (due to the imperceptivity of the stimulation performed, there will be a placebo machine and another that applies the treatment).

At the end of the study, the results obtained between the different groups of patients will be able to be compared; those additionally treated with a device, those treated with a placebo device and those in the standard rehabilitation procedure without a device.

Connect with a study center

  • University of Las Palmas de Gran Canaria

    Las Palmas de Gran Canaria, Las Palmas 35016
    Spain

    Site Not Available

  • University of Las Palmas de Gran Canaria

    Las Palmas de Gran Canaria 2515270, Las Palmas 35016
    Spain

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.